All In Biotech

Drug Trial Radar · NCT00638547

Intrathecal Enzyme Replacement for Hurler Syndrome

Intrathecal Enzyme Replacement Therapy For Patients With Mucopolysaccharidosis Type I (Hurler Syndrome)

Last checked: Nov 20, 2026Latest source record: Dec 3, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Jan 2, 2008

Primary completion

Feb 18, 2017

Study completion Nov 18, 2018

Sponsor

Lead sponsor
Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 19, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 months, up to 3 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This protocol will examine whether the enzyme alpha-L-iduronidase (Laronidase), delivered into the spinal fluid of patients with Hurler syndrome at intervals before and after bone marrow transplant, is a safe and effective approach to slow the neurologic degeneration seen in Hurler patients undergoing transplantation.

Conditions

  • Hurler Syndrome

Interventions

  • IRT LaronidaseDrug

    Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup. Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To demonstrate the efficacy of intrathecally delivering alpha-L-iduronidase in patients with mucopolysaccharidosis type I in decreasing neurodevelopmental deteriorationTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Minnesota, Fairview

    Minneapolis, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.